Here, we have analysed the methylation status of the FANCF CpG island in a series of ovarian cancer patients treated on a clinical trial to address the possibility that methylation of FANCF is a determinant of clinical response and outcome in ovarian cancer patients treated with cisplatin-based chemotherapy. This evidence concerns the gene FANCF and ovarian carcinoma.